Top Markets
Coin of the day
Vincerx Pharma, Inc. Vincerx Pharma, Inc.

Vincerx Pharma, Inc.

VINC
株式のランク #40876
Vincerx Pharma, Inc. is a biopharmaceutical firm currently in the clinical... Vincerx Pharma, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering and advancing innovative treatments for cancer, specifically addressing areas of high medical need within the U.S. Its primary therapeutic asset is VIP152, an inhibitor targeting cyclin-dependent kinase-9 (CDK9), designed for individuals battling advanced forms of cancer. Beyond this lead candidate, the company's pipeline features several preclinical-stage projects: VIP217, an orally administered PTEFb/CDK9 inhibitor; VIP236, a small molecule drug conjugate aimed at solid tumor treatment; and VIP943 and VIP924, both geared towards treating blood cancers. Established in 2019, Vincerx Pharma is based in Palo Alto, California.
株価
$0.0127
最終同期: 2026-08-12
時価総額
$66.48K
変化(1日)
-2.31%
変化(1年)
-67.44%
US
取引 Vincerx Pharma, Inc. (VINC)

カテゴリー

Vincerx Pharma, Inc.(VINC)の配当利回りの履歴
Vincerx Pharma, Inc.(銘柄コード: VINC)の配当利回り(TTM)は2026時点で0です。
過去5年間の平均配当利回り: 0.00%
Vincerx Pharma, Inc.(VINC)の2026から2026までの配当利回りの履歴
各年末時点の配当利回り(TTM)
配当利回り 変化
提供された日付のデータは十分ではありません。
類似企業または競合他社の配当利回り(TTM)